Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators.
Matei AE , Beyer C , Györfi AH , Soare A , Chen CW , Dees C , Bergmann C , Ramming A , Friebe A , Hofmann F , Distler O , Schett G , Distler JHW 
Ann Rheum Dis.2018 Jan 08 ; ():.
PubMedで表示
Google翻訳で開く
(30view , 0users)
Stimulators of soluble guanylate cyclase (sGC) are currently investigated in clinical trials for the treatment of fibrosis in systemic sclerosis (SSc). In this study, we aim to investigate the role of protein kinases G (PKG) as downstream mediators of sGC-cyclic guanosine monophosphate (cGMP) in SSc.
PMID: 29311148 [PubMed - as supplied by publisher]
PMID: 29311148 [PubMed - as supplied by publisher]
関連論文
- Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis.
- Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling.
- Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
- [Review] The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review.
- Inhibition of the TGFβ signalling pathway by cGMP and cGMP-dependent kinase I in renal fibrosis.